Dr. Jonathan Michael Anzmann, MD, MS

Dr. Anzmann practices at Pleasant Acres Operating in Philadelphia, Pennsylvania.

Dr. Anzmann's NPI, 1891291878, was assigned on March 30, 2018. Dr. Anzmann holds Pennsylvania license MD482088.

Dr. Anzmann's primary practice is Pleasant Acres Operating, at 8301 E Roosevelt Blvd, Philadelphia, PA 19152 in Philadelphia County. The practice phone is (717) 840-7100.

Dr. Anzmann's primary practice is Pleasant Acres Operating in Philadelphia, Pennsylvania. Dr. Anzmann is also affiliated with UPMC Hanover. The medical group on file is PinnacleHealth Hospitalist Services. Dmand AI also links Dr. Anzmann to 1 more hospital, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anzmann practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Anzmann's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Anzmann's licenses on file in 2 states: Pennsylvania and Georgia.

CMS data shows 720 Medicare services from Dr. Anzmann across 4 procedure codes in 2024, for 340 Medicare patients. Medicare paid $72,530 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 340 Medicare patients who saw Dr. Anzmann in 2024. The largest group is 75 to 84, with 135 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Anzmann's median patient age at 76, with 49% women.

In 2024, Dr. Anzmann wrote 305 Medicare Part D claims for 149 patients. 93% of them were for generic drugs. CMS names the drug for 107 of them, across 5 drugs with 11 or more claims each, at $595 in total drug cost. In 2023, CMS named 40 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Anzmann for performance year 2024, reported as part of a group. Dr. Anzmann accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Dr. Anzmann from 2 drug and device companies from 2019 to 2021. Food and beverage make up the largest share, 100% of the total. Esperion Therapeutics, Inc. paid the most, $124.